Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Alan List is Director at Tuhura Biosciences, Inc.. OQRO lists 1 transaction filed with the SEC under this name, the latest on Feb 17, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
Feb 12, 2026156Kdisclosed Feb 17
DetailsOfficial recordAlan List has no open-market purchase on record since 2022. Sales in 3 of the 5 years since 2022.
Alan List reported 0 open-market purchases and 6 sales since 2022; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2024 | — | $13K3×3 trades |
| 2023 | — | $16K2×2 trades |
| 2022 | — | $16K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Alan List has no open-market purchase on record since 2022. Sales in 3 of the 5 years since 2022.
In SEC filings since 2022: no open-market purchase is on record; the latest open-market sale is from 2024.
Precision Biosciences (DTIL), from 2022 to 2024: 0 purchases and 6 sales.
Alan List reported 0 open-market purchases and 6 sales here, 2022 to 2024.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.